DexCom stock blew up after the company mismanaged its investments in new growth opportunities. Shares could be ready to rebound now that the company has introduced a new product, Jacob Sonenshine writes in this week’s edition of Barron’s. DexCom, which is expected to sell the devices to just under three million people this year, has plenty of growth potential. It even announced this week Stelo, a new CGM for noninsulin Type 2 diabetics and prediabetics, the author adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
Questions or Comments about the article? Write to editor@tipranks.com